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Seckel syndrome (SCKL) is a rare, genetically heterogeneous disorder, with dysmorphic facial appearance, growth
retardation, microcephaly, mental retardation, variable chromosomal instability, and hematological disorders. To
date, three loci have been linked to this syndrome, and recently, the gene encoding ataxia-telangiectasia and Rad3-
related protein (ATR) was identified as the gene mutated at the SCKL1 locus. The ATR mutation affects splicing
efficiency, resulting in low levels of ATR in affected individuals. Elsewhere, we reported increased instability at
common chromosomal fragile sites in cells lacking the replication checkpoint gene ATR. Here, we tested whether
cells from patients carrying the SCKL1 mutation would show increased chromosome breakage following replication
stress. We found that, compared with controls, there is greater chromosomal instability, particularly at fragile sites,
in SCKL1-affected patient cells after treatment with aphidicolin, an inhibitor of DNA polymerase a and other
polymerases. The difference in chromosomal instability between control and patient cells increases at higher levels of
aphidicolin treatment, suggesting that the low level of ATR present in these patients is not sufficient to respond
appropriately to replication stress. This is the first human genetic syndrome associated with increased chromosome
instability at fragile sites following replication stress, and these findings may be related to the phenotypic findings
in patients with SCKL1.
Seckel syndrome (SCKL [MIM #210600]) is a rare, ge-
netically heterogeneous autosomal recessive disorder of
proportionate dwarfism, mental retardation, and char-
acteristic faces marked by microcephaly, craniosynosto-
sis, receding forehead, narrow face, large beaked nose,
and micrognathia, giving the face an asymmetric “bird-
like” appearance. Since SCKL was first described in 1960
(Seckel 1960), 170 cases have been reported, but there
is considerable heterogeneity in their clinical character-
istics. This disorder shares many clinical characteristics
with Nijmegen breakage syndrome (MIM #251260) and
LIG4 syndrome (MIM #606593), both of which are syn-
dromes involving DNA damage-response genes. Some
patients exhibit cafe´-au-lait spots (Woods et al. 1995;
Børglum et al. 2001; Kilinc¸ et al. 2003) and immuno-
logical and hematological disorders, including frequent
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infections, anemia (Lilleyman 1984), pancytopenia; one
patient received a diagnosis of acute myeloid leukemia
(Hayani et al. 1994).
There have been mixed reports of chromosome insta-
bility in cells from patients with SCKL. Nine patients have
been reported to have increased chromosomal instability
after treatment with mitomycin C (MMC) (Butler et al.
1987; Syrrou et al. 1995; Woods et al. 1995; Bobabilla-
Morales et al. 2003), and two patients with spontaneous
chromosomal instability have been reported (Butler et
al. 1987; Woods et al. 1995). However, cells from two
patients with unknown mutations have been reported to
be resistant to MMC (Abou-Zahr et al. 1999). Increased
sister-chromatid exchange (SCE) has also been observed
(Cervenka et al. 1979; Syrrou et al. 1995).
It is not surprising, given the varied clinical findings,
that several loci have been linked to SCKL. The first locus,
SCKL1, was mapped by Goodship et al. (2000) to
3q22.1-q24 in two consanguineous Pakistani families.
SCKL2 was mapped by Børglum et al. (2001) to
18p11.31-q11.2 in a consanguineous Iraqi family, and
SCKL3 was mapped, by linkage analysis by Kilinc¸ et al.
(2003), to a 1.18-cM region on 14q in five Turkish fami-
lies. Kilinc¸ et al. (2003) also noted that the mutation in
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Figure 1 Pedigrees of family with SCKL and western blot show-
ing reduced ATR protein levels in affected patients. A and B, Pedigrees
of the two Pakistani families with SCKL (SCKL1) included in this
study. Identification numbers of the lymphoblast cell lines derived from
these family members are noted below their respective symbols. C,
Western blot of lymphoblast cell lines from these family members and
two unrelated control lymphoblast lines (LB-5 and LB-12) probed with
a-ATR. The blot was stripped and reprobed with a-tubulin to indicate
relative protein-loading levels.
four other Turkish families did not show linkage to any
of the three Seckel loci, indicating that additional genetic
heterogeneity remains.
Recently, O’Driscoll et al. (2003) identified ATR
(ataxia-telangiectasia and Rad3-related protein) as the
gene mutated at the SCKL1 locus. The mutation is a
silent 2101ArG transition in ATR exon 9 that results
in increased aberrant splicing, either skipping of exon 9
or use of cryptic splice donors within exon 9, both of
which introduce a frameshift and stop codon in exon
10. Patients homozygous for the mutation have a low
level of correctly spliced ATR, resulting in low levels of
ATR protein, as monitored by western blot (O’Driscoll
et al. 2003).
ATR is a member of the PI3K family, is closely related
to ATM, and functions in cell-cycle checkpoint and DNA-
repair pathways. It is a key member of the intra-S and
G2/M checkpoints and responds primarily to replication
stress, such as that caused by hydroxyurea, aphidicolin,
and hypoxia (Cliby et al. 1998; Cortez et al. 2001;
Nghiem et al. 2001; Hammond et al. 2002). When ac-
tivated, ATR stabilizes stalled replication forks (Lopes
et al. 2001; Tercero and Diffley 2001), inhibits late origin
firing (Tercero and Diffley 2001), and blocks progression
from G2 into mitosis (Nghiem et al. 2001).
We recently determined that ATR is critical for the
normal maintenance of stability at common fragile sites
(Casper et al. 2002). Common fragile sites are specific
loci that preferentially exhibit gaps and breaks on meta-
phase chromosomes under conditions that partially in-
hibit DNA replication (Glover et al. 1984). Although they
are normally stable in cultured human cells, under rep-
licative stress, fragile sites are “hot spots” for SCEs, trans-
locations, and deletions (Glover and Stein 1987, 1988),
as well as integration of foreign DNA (Popescu and
DiPaolo 1989; Rassool et al. 1991; Smith et al. 1992;
Mishmar et al. 1998), and they trigger some gene am-
plification events via a breakage-fusion-bridge cycle (Kuo
et al. 1994; Coquelle et al. 1997; Hellman et al. 2002).
Numerous studies have shown that fragile sites are un-
stable in tumors (reviewed in Huebner and Croce
[2001]). Although the mechanism of instability at fragile
sites is not yet fully understood, it is now known that
the ATR-checkpoint pathway plays a critical role. We
previously found that ATR deficiency results in a 5–20-
fold increase in chromosomal gaps and breaks at fragile
sites after aphidicolin treatment, as well as in the ap-
pearance of fragile site breaks even without the addition
of replication inhibitors (Casper et al. 2002). Therefore,
we hypothesized that cells from SCKL1-affected patients
with a hypomorphic mutation in ATR would have in-
creased chromosome instability, especially at fragile sites,
following replication stress.
To test this hypothesis, we obtained Epstein-Barr virus
(EBV)–transformed lymphoblast cell lines DK0060,
DK0061, DK0062, DK0063, and DK0066 from two
families with SCKL1 from J. Goodship (Newcastle Uni-
versity, Newcastle-upon-Tyne, United Kingdom) (Good-
ship et al. 2000; O’Driscoll et al. 2003) and LB-5 and
LB-12, two EBV-transformed lymphoblast lines estab-
lished from normal individuals. O’Driscoll et al. (2003)
elsewhere reported a silent mutation in ATR in these two
families with SCKL1, which resulted in aberrant ATR
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Figure 2 Metaphase showing an example of FISH for identifi-
cation of fragile sites. This representative metaphase is from lympho-
blast cell line DK0061, after treatment with 0.4 mM aphidicolin.
FRA3B is indicated by hybridization with YAC probe 850A6 (green);
both homologs are broken. FRA16D is indicated by hybridization with
BAC probe 264L1 (red); both homologs are broken.
Figure 3 Cells from patients with SCKL1 have increased fragile-
site expression. A, Average total chromosome gaps and breaks. np
metaphases from each of two replicates for each condition. Frag-50
ile-site induction was achieved by addition of 0.4 mM aphidicolin 48
h before harvest. Error bars indicate the 95% CI. B and C, Frequency
of FRA3B (B) and FRA16D (C) expression in cell lines from patients
with SCKL1 and control individual; hybridizations fromn  100
each of two replicates for each condition. Fragile-site induction was
achieved by addition of 0.4 mM aphidicolin 48 h before harvest. Error
bars indicate the SE.
transcripts and a reduced ATR protein level in fibroblasts
from one affected individual. We harvested cellular pro-
tein from all the lymphoblastoid cell lines for western
blot analysis of ATR. ATR was detected with a rabbit
polyclonal antibody generated against amino acids 1–
20 of ATR, and the membrane was then stripped and
reprobed with anti-tubulin. As expected, we found that
cell lines DK0063 and DK0066 from affected patients
have reduced ATR protein levels, compared with their
heterozygous parent lines DK0060 and DK0062 and
with normal control lines DK0061, LB-5, and LB-12 (fig.
1A–1C).
We next treated these lymphoblast lines with 0.4 mM
aphidicolin for 48 h and harvested them for chromo-
some preparations, under standard conditions. Meta-
phase spreads were examined for total chromosomal
gaps and breaks, and FRA3B and FRA16D were de-
tected by FISH analysis by use of probes within these
fragile sites (YAC 850A6 and BAC264L1 [RP-11], re-
spectively). Probe labeling, hybridization, and immuno-
logic detection were performed according to standard
protocols (Wilke et al. 1996). Biotin-labeled probes were
detected with avidin-FITC followed by anti–avidin-
FITC; digoxigenin-labeled probes were detected with
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Figure 4 The difference in fragile site breaks between patient and control cells increases at higher levels of aphidicolin treatment. Cells
were treated with 0.1, 0.3, 0.5, 0.7, or 0.9 mM aphidicolin 48 h before harvest. Of DK0066 metaphases analyzed at high aphidicolin concen-
trations, 16%–38% had a “shattered” appearance and were not included in these calculations; thus, the figures reported are underestimates
(indicated by a double asterisk [**]). A, Average total chromosome gaps and breaks. metaphases from each of two replicates for eachnp 25
condition. Error bars indicate the 95% CI. B and C, Frequency of FRA3B (B) and FRA16D (C) expression in cell lines from a patient with
SCKL and a control individual; hybridizations from each of two replicates for each condition. Error bars indicate the SE. D, Examplen  50
of a “shattered” metaphase in the affected cell line DK0066 after treatment with 0.5 mM aphidicolin for 48 h before harvest.
rhodamine-conjugated antibody followed by Texas Red
anti-goat. Chromosomes were counterstained with DAPI
(4′,6-diamidino-2-phenylindole) (fig. 2). For all analyses,
at least 50 cells from each of two replicates were scored
for each data point, and a one-tailed t test was employed
for comparisons of average overall gaps and breaks and
for comparisons of the frequency of gaps and breaks at
specific fragile sites.
We found that, after aphidicolin treatment, the average
total gaps and breaks per cell was increased 2.5–7-fold
in SCKL1-affected patient lines, as compared with par-
ent and control lines (fig. 3A). We did not observe any
significant increase in spontaneous chromosomal insta-
bility in untreated cells. It is likely that the observed
increase in chromosomal breaks is directly attributable
to instability at fragile sites, since the majority of gaps
and breaks observed after aphidicolin treatment occur
at common fragile sites (Glover et al. 1984). To test this
directly, we examined gaps and breaks at fragile sites
FRA3B and FRA16D, two of the most frequently ex-
pressed common fragile sites. We found that FRA3B
showed gaps and breaks 2–5-fold more often in SCKL1-
affected patient lines than in parents and controls (fig.
3B). FRA16D is broken 2–5-fold more often in patient
line DK0066, whereas FRA16D is not broken signifi-
cantly more often in patient line DK0063 than in parent
line DK0062 (fig. 3C). After treatment with 0.4 mM
aphidicolin, we found that 22%–44% of all breaks oc-
curred at FRA3B and FRA16D, which is consistent with
earlier reports that the great majority of aphidicolin-
induced gaps and breaks are at !20 fragile sites (Glover
et al. 1984). These data suggest that breakage specifically
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Table 1
P Values of the Difference in Breaks after Aphidicolin Treatment
BREAKS AND LYMPHOBLAST
CELL LINEa
P VALUES AFTER APHIDICOLIN TREATMENT WITH
.1 mM .3 mM .5 mM .7 mM .9 mM
Total:
LB-5 vs. DK0060 .09799 .47319 .34485 .00630 .03574
LB-5 vs. DK0066 .02672 .00136 b82.86# 10 b54.37# 10 b41.14# 10
DK0060 vs. DK0066 .21772 .00124 b82.32# 10 b41.34# 10 b42.91# 10
At FRA3B:
LB-5 vs. DK0060 1.0 1.0 .1652 .0513 .5416
LB-5 vs. DK0066 .6212 .0072 101.00# 10 b76.66# 10 b41.67# 10
DK0060 vs. DK0066 .9999 .0072 86.20# 10 .0045b .0030b
At FRA16D:
LB-5 vs. DK0060 1.0 .3311 1.0 .6133 .8143
LB-5 vs. DK0066 .6212 .0165 62.17# 10 b55.09# 10 .0017b
DK0060 vs. DK0066 .6212 .1676 62.17# 10 b47.70# 10 .0071b
a LB-5pnormal; DK0060pheterozygote; DK0066paffected.
b Of DK0066 metaphases analyzed, 16%–38% had a “shattered” appearance and were not included
in these calculations; thus, the significance reported is an underestimate.
at fragile sites is the cause of increased chromosomal
instability in these SCKL1-affected cells after aphidicolin
treatment.
Since the ATR mutation in these SCKL1-affected pa-
tient lines is hypomorphic, we suspected that challenging
these cells with higher doses of aphidicolin would reveal
a threshold level of replication stress that these cells can
accommodate, beyond which there is not enough func-
tional ATR protein to respond appropriately. To test this
hypothesis, we treated cell lines LB-5, DK0060, and
DK0066 with increasing levels of aphidicolin—0.1–0.9
mM—for 48 h, and we examined metaphases from these
cells in the same manner as described above. Following
aphidicolin treatment at all concentrations, the average
total breaks per cell was greater in SCKL1-affected cells
than in controls (fig. 4A), and we found that the signifi-
cance of this difference in average total breaks per cell
increases at higher aphidicolin concentrations (table 1).
The difference in gaps and breaks at both FRA3B and
FRA16D between patients and controls is also more sig-
nificant at higher aphidicolin concentrations (fig. 4B and
4C and table 1). We found that 10%–47% of all gaps
and breaks occurred at just these two fragile sites. In the
patient cell line DK0066 with 0.5 mM, 0.7 mM, and 0.9
mM aphidicolin treatment, we observed that 16%–38%
of metaphases analyzed had a “shattered” appearance,
with extreme chromosomal damage (as shown in fig. 4D).
We did not observe any metaphases of this type in the
normal LB-5 line or in the parental cell line DK0060.
We did not see any “shattered” metaphases in the pre-
vious experiment after treatment with just 0.4 mM
aphidicolin.
In summary, we have found that SCKL1-affected pa-
tient cells with hypomorphic mutations in ATR have in-
creased instability at fragile sites after aphidicolin treat-
ment and that the significance of the difference in breaks
between patient and control cells increases at higher lev-
els of aphidicolin treatment, suggesting a threshold of
replication stress for SCKL1 cells. Given the known cell-
cycle checkpoint function of ATR (Abraham 2001), this
increase in instability is probably due to improper pro-
gression into mitosis after failure to delay at the S-phase
or G2/M checkpoints in response to replication stalling.
SCKL1 is the first human disease to be associated with
mutations in ATR and with increased chromosome
breakage at fragile sites, and these results affirm our
earlier work that showed that ATR deficiency results in
increased fragile-site instability (Casper et al. 2002). Fur-
thermore, these results support earlier work indicating
that the silent mutation in ATR in these families is causa-
tive for the SCKL1 phenotype (O’Driscoll et al. 2003).
The malformations seen in these affected individuals
may result from inappropriate checkpoint responses and
chromosome breakage, leading to cell death at times of
replicative stress during development. Since cancer or
leukemia has not been reported in the two affected pa-
tients from these families, the ATR hypomorphic muta-
tion and increased fragile site instability may not con-
tribute to tumor initiation. However, both affected in-
dividuals are young (aged !15 years) (Goodship et al.
2000), and continued observation of the clinical phe-
notype of these patients offers the unique opportunity
to understand the in vivo consequences of such insta-
bility on tumor initiation or progression. Since cells from
these patients manage low levels of replication stress
nearly as well as do normal cells but respond inappro-
priately at higher levels of stress, it is possible that pa-
tients with this mutation would be more likely to mani-
fest clinical phenotypes in response to conditions known
to challenge the ATR checkpoint pathway or induce
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fragile sites, such as folic acid deficiency. Folic acid de-
ficiency, which is common worldwide, is known to in-
duce breaks at common fragile sites (Glover et al. 1984),
and has been associated with anemia, elevated serum
homocysteine (which is associated with coronary artery
disease and stroke), neural tube defects during preg-
nancy, and cancer development (Blount et al. 1997;
Koury et al. 1997; Verhaar et al. 2002; Geisel 2003). In
addition to the insight offered by clinical phenotypes,
we believe that the hypomorphic ATR mutation itself
will prove to be a useful tool for studying the conse-
quences of ATR deficiency and impaired cellular re-
sponses to replication stalling. The level of ATR protein
present after this mutation is high enough to prevent the
cell death phenotype of ATR-null cells yet is low enough
to result in deficient cell-cycle checkpoint responses in
response to replication stress. Finally, it will be of interest
to investigate fragile-site instability in cells from SCKL-
affected patients that are linked to mutations on
18p11.31-q11.2 (SCKL2) and 14q (SCKL3), as well as
from other patients with genetically undefined SCKL, to
determine whether these complementation groups have
mutations in genes related to the ATR checkpoint
pathway.
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